Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

A 17-year experience of abobotulinumtoxina in cervical dystonia.

Vivancos-Matellano F, Ybot-Gorrin I, Diez-Tejedor E.

Int J Neurosci. 2012 Jul;122(7):354-7. doi: 10.3109/00207454.2012.665971. Epub 2012 Mar 20. Erratum in: Int J Neurosci. 2012 Dec;122(12):767.

PMID:
22329596
[PubMed - indexed for MEDLINE]
2.

Botulinum toxin type A and cervical dystonia: a seven-year follow-up.

Camargo CH, Teive HA, Becker N, Munhoz RP, Werneck LC.

Arq Neuropsiquiatr. 2011 Oct;69(5):745-50.

PMID:
22042174
[PubMed - indexed for MEDLINE]
Free Article
3.

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S; Global Dysport Cervical Dystonia Study Group.

Parkinsonism Relat Disord. 2010 Jun;16(5):316-23. doi: 10.1016/j.parkreldis.2010.03.002. Epub 2010 Mar 31.

PMID:
20359934
[PubMed - indexed for MEDLINE]
4.

AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.

Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P.

J Neural Transm. 2013 Feb;120(2):299-307. doi: 10.1007/s00702-012-0872-1. Epub 2012 Aug 10.

PMID:
22878514
[PubMed - indexed for MEDLINE]
5.

Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.

Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD.

Clin Ther. 2007 Jul;29(7):1325-37. Review.

PMID:
17825685
[PubMed - indexed for MEDLINE]
6.

Cervical dystonia: clinical and therapeutic features in 85 patients.

Camargo CH, Teive HA, Becker N, Baran MH, Scola RH, Werneck LC.

Arq Neuropsiquiatr. 2008 Mar;66(1):15-21.

PMID:
18392407
[PubMed - indexed for MEDLINE]
Free Article
7.

Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study.

Ruiz PJ, Castrillo JC, Burguera JA, Campos V, Castro A, Cancho E, Chacón J, Vara JH, del Val JL, Garcia EL, Miquel F, Sanz P, Vela L.

J Neurol. 2011 Jun;258(6):1055-7. doi: 10.1007/s00415-010-5880-1. Epub 2011 Jan 1.

PMID:
21197540
[PubMed - indexed for MEDLINE]
8.

Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.

Coleman C, Hubble J, Schwab J, Beffy JL, Picaut P, Morte C.

Int J Neurosci. 2012 Jul;122(7):358-62. doi: 10.3109/00207454.2012.668725. Epub 2012 May 11.

PMID:
22356470
[PubMed - indexed for MEDLINE]
9.

A long-term follow-up of botulinum toxin A in cervical dystonia.

Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K.

Neurol Res. 2009 Jun;31(5):463-6. doi: 10.1179/174313209X405137. Epub 2009 Mar 11.

PMID:
19278576
[PubMed - indexed for MEDLINE]
10.

Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.

Felicio AC, Godeiro-Junior C, de Carvalho Aguiar P, Borges V, Silva SM, Ferraz HB.

Neurol Sci. 2009 Aug;30(4):291-4. doi: 10.1007/s10072-009-0097-8. Epub 2009 May 26.

PMID:
19468681
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL.

Mov Disord. 2005 Jul;20(7):783-91.

PMID:
15736159
[PubMed - indexed for MEDLINE]
12.

Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.

Hefter H, Spiess C, Rosenthal D.

J Neural Transm. 2014 May;121(5):513-9. doi: 10.1007/s00702-013-1127-5. Epub 2013 Dec 6.

PMID:
24311063
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.

Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Růzicka E, Jech R, Sławek J, Ahmed F.

Mov Disord. 2005 Aug;20(8):937-44. Erratum in: Mov Disord. 2005 Aug;20(8):1089. Råuzizka, Evzen [corrected to Růzicka, Evzen].

PMID:
15810022
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.

Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, Jech R, Roth J, Brenneis C, Müller J, Schnider P, Auff E, Richardson A, Poewe W.

J Neurol. 2001 Dec;248(12):1073-8.

PMID:
12013585
[PubMed - indexed for MEDLINE]
15.

Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.

Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A.

Mov Disord. 2004 Mar;19(3):303-8.

PMID:
15022184
[PubMed - indexed for MEDLINE]
16.

Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.

Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group.

Mov Disord. 2008 Mar 15;23(4):510-7.

PMID:
18098274
[PubMed - indexed for MEDLINE]
17.

Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.

Laubis-Herrmann U, Fries K, Topka H.

Eur Neurol. 2002;47(4):214-21.

PMID:
12037435
[PubMed - indexed for MEDLINE]
18.

The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study.

Werdelin L, Dalager T, Fuglsang-Frederiksen A, Regeur L, Karlsborg M, Korbo L, Munck O, Winge K.

Clin Neurophysiol. 2011 Nov;122(11):2305-9. doi: 10.1016/j.clinph.2011.04.012. Epub 2011 Jun 1.

PMID:
21636319
[PubMed - indexed for MEDLINE]
19.

Botulinum toxin therapy for cervical dystonia.

Jankovic J.

Neurotox Res. 2006 Apr;9(2-3):145-8. Review.

PMID:
16785112
[PubMed - indexed for MEDLINE]
20.

Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.

Factor SA, Molho ES, Evans S, Feustel PJ.

Mov Disord. 2005 Sep;20(9):1152-60.

PMID:
15954134
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk